Unfit patients even have the choice of venetoclax as well as obinutuzumab (VO) as frontline therapy. This relies on the section III trial that compared VO with ClbO in elderly/unfit people.113 VO was remarkable in terms of response price and development-no cost survival, and experienced a equivalent safety profile. On this demo VO was administered